Sanofi's Tzield Secures FDA Approval To Delay Stage 3 Type 1 Diabetes Onset In Children Aged One And Above, Expanding From Prior Eight-Year Age Limit

Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

• Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3
• Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D